Search Results for: MET

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel SLC26A4 solute carrier family 26 member 4
  • Multifunctional anion exchangers
  • Defective SLC26A4 causes Pendred syndrome (PDS)
  • Deafness, autosomal recessive
  • Thyroid dyshormonogenesis; Dyshormogenetic goiter
Novel CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Congenital generalized lipodystrophy (CGL)
Novel CAMSAP3 calmodulin regulated spectrin associated protein family member 3
Novel FOXA3 forkhead box A3
  • Regulation of gene expression in beta cells
Novel KCND2 potassium voltage-gated channel subfamily D member 2
  • Voltage gated Potassium channels
  • Phase 1 - inactivation of fast Na+ channels
  • Enflurane
  • Disopyramide
  • Imipramine
  • Promethazine
  • Miconazole
  • Dalfampridine
Novel KLK2 kallikrein related peptidase 2
  • Activation of Matrix Metalloproteinases
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
Novel MRPL17 mitochondrial ribosomal protein L17
  • Mitochondrial translation initiation
  • Mitochondrial translation elongation
  • Mitochondrial translation elongation
  • Mitochondrial translation termination
Novel PABPC1 poly(A) binding protein cytoplasmic 1
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Deadenylation of mRNA
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Translation initiation complex formation
  • Regulation of expression of SLITs and ROBOs
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
Novel RASSF7 Ras association domain family member 7
Novel SH3KBP1 SH3 domain containing kinase binding protein 1
  • EGFR downregulation
  • Negative regulation of MET activity
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Reelin signalling pathway
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Novel SLC26A3 solute carrier family 26 member 3
  • Multifunctional anion exchangers
  • Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1)
Novel SND1-IT1 SND1 intronic transcript 1
TP53 tumor protein p53
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Factors involved in megakaryocyte development and platelet production
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Osteosarcoma
  • Adrenal carcinoma
  • Thyroid cancer
  • Breast cancer
  • Basal cell carcinoma
  • Malignant melanoma
  • Pancreatic cancer
  • Gastric cancer
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Small cell lung cancer
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Glioma
  • Squamous cell carcinoma
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Cancer of the anal canal
  • Hepatocellular carcinoma
  • Choriocarcinoma
  • Vulvar cancer
  • Choroid plexus papilloma
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Hairy-cell leukemia
  • Bladder cancer
  • Chronic lymphocytic leukemia (CLL)
  • Penile cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Colorectal cancer
  • Laryngeal cancer
  • Chronic myeloid leukemia (CML)
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Acetylsalicylic acid
  • Nadroparin
  • Choriocarcinoma
  • Penile cancer
  • Burkitt lymphoma
  • Oral cancer
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Multiple myeloma
  • Small cell lung cancer
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Osteosarcoma
  • Kaposi's sarcoma
  • Laryngeal cancer
  • Breast cancer
  • Ovarian cancer
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Urea
  • Gastric cancer
  • Colorectal cancer
  • Endometrial Cancer
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Thyroid cancer
  • Hepatocellular carcinoma
FAS Fas cell surface death receptor
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • Hodgkin lymphoma
  • Esophageal cancer
  • Chronic lymphocytic leukemia (CLL)
  • Adult T-cell leukemia
CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Glioma
  • Malignant melanoma
  • Cervical cancer
CDKN2B cyclin dependent kinase inhibitor 2B
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Malignant pleural mesothelioma
  • Osteosarcoma
  • Type II diabetes mellitus

Page 1 out of 7 pages